Ticker Details
Axon Holdings S.A. Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.
IPO Date:	June 11, 2015
Sector:	Industrials
Industry:	Aerospace and Defense
Market Cap:	$34.13B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$3.21 | 2.40%
Avg Daily Range (30 D):	$13.65 | 2.57%
Avg Daily Range (90 D):	$12.19 | 2.08%

Institutional Daily Volume
Avg Daily Volume:	.62M
Avg Daily Volume (30 D):	.82M
Avg Daily Volume (90 D):	.72M

Trade Size
Avg Trade Size (Sh.):	66
Avg Trade Size (Sh.) (30 D):	21
Avg Trade Size (Sh.) (90 D):	20

Institutional Trades
Total Institutional Trades:	3,496
Avg Institutional Trade:	$16.45M
Avg Institutional Trade (30 D):	$31.24M
Avg Institutional Trade (90 D):	$33.81M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$28.77M
Avg Closing Trade (30 D):	$57.01M
Avg Closing Trade (90 D):	$60.94M
Avg Closing Volume:	86.68K

News

Feb 13, 2026 @ 3:37 PM Amazon's Lost Puppy Super Bowl Commercial Backfire... Source: Chris Katje

Feb 1, 2026 @ 7:31 PM UnitedHealth, Trade Desk, And Unity Are Among Top ... Source: Nabaparna Bhattacharya

Jan 13, 2026 @ 3:00 PM LVT Ranked No. 1 Innovative Leader in 2025 Frost R... Source: Not Specified

Jan 8, 2026 @ 5:14 AM Is Axon (AXON) Stock a Buy in 2026? Source: Jennifer Saibil

Jan 4, 2026 @ 8:55 PM How Trump Moved Stocks In 2025: Crypto, Drones, He... Source: Erica Kollmann

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$-.03	$.46	$1.14
Diluted EPS	$-.03	$.44	$1.08
Revenue	$710.64M	$668.54M	$603.63M
Gross Profit	$427.35M	$403.74M	$365.74M
Net Income / Loss	$-2.19M	$36.12M	$87.98M
Operating Income / Loss	$-2.13M	$-1.04M	$-8.79M
Cost of Revenue	$283.29M	$264.8M	$237.89M
Net Cash Flow	$808.68M	$-477.3M	$638M
PE Ratio

Splits
Sep 28, 2007	1:600
Nov 30, 2004	2:1
Apr 30, 2004	2:1
Feb 11, 2004	3:1